Pillar Biosciences Revenue and Competitors

Natick, MA USA

Location

$65.9M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Pillar Biosciences's estimated annual revenue is currently $15.2M per year.(i)
  • Pillar Biosciences received $18.0M in venture funding in May 2016.
  • Pillar Biosciences's estimated revenue per employee is $155,000
  • Pillar Biosciences's total funding is $65.9M.

Employee Data

  • Pillar Biosciences has 98 Employees.(i)
  • Pillar Biosciences grew their employee count by -17% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.2M10%N/AN/A
#3
$4.2M2735%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$1.4M929%N/AN/A
#6
$235M255-31%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.3M340%N/AN/A
#10
$1.9M12-8%N/AN/A
Add Company

Pillar Biosciences aims to "Make Precision Medicine Accessible" by developing and manufacturing targeted next-generation sequencing (NGS)-based assays and software for today's high-throughput specialty NGS laboratories. Through our SLIMamp technology (a multiplex overlapping PCR chemistry) Pillar offers a streamlined, robust and economical workflow with high mapping and on-target metrics. In conjunction with the SLIMamp assay technology, Pillar Biosciences has an informatics pipeline called the Pillar Variant Analysis Toolkit (PiVAT) that is not only highly accurate, enabling somatic variant calls down to 1% allele frequency without use of Unique Identifiers (UIDs), but also fast and efficient, returning valuable sample data quickly. For higher-sensitivity applications such as cell-free DNA analyses, Pillar Biosciences has developed a dedicated assay technology for cell-free DNA that uses UID methodology, to work with the PiVAT pipeline to drive sensitivity down to 0.1%-0.2%.

keywords:Biotechnology,Healthcare,Medical Diagnostics,Pharmaceuticals

$65.9M

Total Funding

98

Number of Employees

$15.2M

Revenue (est)

-17%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Pillar Biosciences News

2022-04-17 - Global Leaders to Present Breakthroughs in Liquid Biopsy ...

... Exact Sciences/Thrive, Grail, Guardant, IV BioHoldings (IVBH), Natera, Pillar Biosciences and StageZero Life Sciences.

2022-04-06 - Pillar Biosciences Presents New Clinical Validation Data ...

Pillar Biosciences is a global oncology solutions company delivering in-vitro diagnostics (IVD) that provide accurate, robust, timely,...

2022-03-22 - Pillar Biosciences Expands Leadership Team with ...

Pillar Biosciences is a global oncology solutions company delivering in-vitro diagnostics (IVD) that provide accurate, robust, timely,...

2020-05-12 - Pillar Biosciences Raises $29.7M in Series C Financing

Pillar Biosciences, a Natick, Mass.- and Shanghai, China-based NGS clinical cancer diagnostics company, closed a $29.7m Series C financing. The round was led by ORI Healthcare Fund. The company intends to use the funds to accelerate the expansion of in vitro diagnostic and research use only pa ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$23.8M105-3%N/A
#2
$11.4M11411%N/A
#3
$26.4M116-1%N/A
#4
$25M1190%N/A
#5
$12.6M1261%N/A

Pillar Biosciences Funding

DateAmountRoundLead InvestorsReference
2016-05-12$18.0MUndisclosedORI Healthcare Fund L.PArticle